Literature DB >> 16026234

Treatment of adults with recurrent malignant glioma.

L Burt Nabors1, John Fiveash.   

Abstract

Virtually all malignant gliomas recur. Treatment options at recurrence have relied upon surgical intervention, radiation therapy or cytotoxic chemotherapy. Unfortunately, none are associated with significant improvements in survival. Advances in treatment options at recurrence have been dependent upon the combination of surgical resection, focal radiation and chemotherapy. Despite aggressive interventions, few patients have meaningful improvements. Current research focuses on novel targeted molecular therapy that will hopeful be able to take advantage of advances in our understanding of the biology of glial neoplasms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16026234     DOI: 10.1586/14737175.5.4.509

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  7 in total

1.  Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma.

Authors:  Antje Ernst-Stecken; Oliver Ganslandt; Ulrike Lambrecht; Rolf Sauer; Gerhard Grabenbauer
Journal:  J Neurooncol       Date:  2006-09-20       Impact factor: 4.130

Review 2.  New molecular targets in angiogenic vessels of glioblastoma tumours.

Authors:  Joshua C Anderson; Braden C McFarland; Candece L Gladson
Journal:  Expert Rev Mol Med       Date:  2008-08-07       Impact factor: 5.600

Review 3.  Improving lesion detection and visualization: implications for neurosurgical planning and follow-up.

Authors:  Piero Picozzi; Miles A Kirchin
Journal:  Neuroradiology       Date:  2007-07       Impact factor: 2.804

Review 4.  Identifying new small molecule anti-invasive compounds for glioma treatment.

Authors:  Jennifer Munson; Michael Bonner; Levi Fried; Jonathan Hofmekler; Jack Arbiser; Ravi Bellamkonda
Journal:  Cell Cycle       Date:  2013-07-15       Impact factor: 4.534

5.  Reduced glioma infiltration in Src-deficient mice.

Authors:  Caren V Lund; Mai T N Nguyen; Geoffrey C Owens; Andrew J Pakchoian; Ashkaun Shaterian; Carol A Kruse; Brian P Eliceiri
Journal:  J Neurooncol       Date:  2006-03-22       Impact factor: 4.130

6.  Are patients open to elective re-sampling of their glioblastoma? A new way of assessing treatment innovations.

Authors:  Taskia Mir; Peter Dirks; Warren P Mason; Mark Bernstein
Journal:  Acta Neurochir (Wien)       Date:  2014-08-02       Impact factor: 2.216

7.  SCO-spondin oligopeptide inhibits angiogenesis in glioblastoma.

Authors:  Romain Bibes; Stéphane Gobron; François Vincent; Carole Mélin; Nicolas Vedrenne; Aurélie Perraud; Francois Labrousse; Marie-Odile Jauberteau; Fabrice Lalloué
Journal:  Oncotarget       Date:  2017-09-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.